

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2023-24

Date: 31.05.2023

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Audited Financial Results for the quarter and year ended
March 31, 2023

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Audited Financial Results of the Company for the quarter and year ended on March 31, 2023 approved by the Board of Directors at their Meeting held on 29.05.2023.

The copy of the results published in the Financial Express and Jansatta dated May 30, 2023 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.



Medicamen Biotech Ltd.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL1993PLC056594
E-mail: cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2023

(all figures are in Rs. Lacs, except EPS)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022
1	Total income from operations (net)	3749.48	2309.14	14034.62	11716.53	14332.96	11716.53
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
3	Net Profit/ (Loss) for the period before tax (after exceptional and /or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	404.60	275.47	1500.20	1490.64	1472.85	1489.71
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	404.60	275.47	1500.20	1490.64	1472.85	1489.71
6	Equity Share Capital	1265.11	1221.66	1265.11	1221.66	1265.11	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	3.25	2.25	12.04	12.20	11.82	12.19
	Diluted:	3.25	2.25	12.04	12.20	11.82	12.19

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2023. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- The other expenses and Employee benefits expenses includes Rs. 3.50 Crores approximately incurred during Financial Year 2022-23 on creating domestic marketing network for Oncology products.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- The figures of the last quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figure upto the period end of the third quarter of the relevant financial year, which were subject to limited review.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi
Chairman

Place: New Delhi
Date: 29.05.2023

ES LIMITED

Faridabad-121004, (Haryana)
Website: <http://www.cenlub.in>
087 Email: investors@cenlub.in
Quarter and Year ended 31 March 2023

(Rs. In Lakhs)

Sl. No.	Particulars	Year Ended		Year Ended	
		31-Mar-22		31-Mar-22	
		(Audited)	(Audited)	(Audited)	(Audited)
1	Total income from operations (net)	1,728.57	5,519.93	1,728.57	5,382.16
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	377.99	903.11	377.99	866.82
3	Net Profit/ (Loss) for the period before tax (after exceptional and /or Extraordinary items)	377.99	903.11	377.99	866.82
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	334.59	699.43	334.59	700.38
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	330.98	665.81	330.98	699.54
6	Equity Share Capital	466.29	466.29	466.29	466.29
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)		4,254.13		3,588.34
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)				
	Basic:	7.18	14.36	7.18	15.02
	Diluted:	7.18	14.36	7.18	15.02

The Audit Committee and subsequently meetings held on 29th May, 2023.

Indian Accounting Standards (Ind AS) read together with the Companies (Indian

to skip the dividend for the year.

ended March 31, 2023 are also available website of BSE (www.bseindia.com)

led, wherever necessary, to make them

FOR CENLUB INDUSTRIES LIMITED

Sd/-

ANSH MITTAL

EXECUTIVE DIRECTOR

DIN: 00041986

imited

Pune - 411 005
1302 Shukrawar Peth, PUNE - 411002

Financial Year Ended 31st March, 2023

(amount in Lakhs)

Sr. No.	Particulars	Year Ended			Previous Year Ended		
		31-Mar-23		31-Mar-22	31-Mar-22		31-Mar-2022
		Audited	Unaudited	Audited	Audited	Audited	Audited
1	Total income from operations (net)	1,263.32	1,206.30	2,167.59	99.97	4.59	4.59
2	Net Profit/(Loss) for the period from ordinary activities (Before Share of Profit/(Loss) of Associate, tax, Exceptional and/or Extraordinary items)	(72.00)	(208.22)	5.07	(99.97)	(266.46)	(266.46)
3	Net Profit/(Loss) for the period before tax (after Share of Profit/(Loss) of Associate, Exceptional and /or Extraordinary items)	(72.00)	(208.22)	5.07	(99.97)	(266.46)	(266.46)
4	Net Profit/ (Loss) for the period after tax (after Share of Profit/ (Loss)	(72.00)	(208.22)	5.07	580.1	2,580.1	2,580.1



Brooks
LABORATORIES LIMITED

BROOKS LAB

CIN No.: L24232HP2002PLC000267,
Dist. Solan H.P.-174101, E-mail: inve

EXTRACTS OF STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE

Sr. No.	Particulars	Standalone			Previous Year Ended		
		Quarter Ended			31/03/2022		
		31-Mar-23	31-Dec-22	31-Mar-22	Audited	Audited	Audited
1	Total income from operations (net)	1,263.32	1,206.30	2,167.59	99.97	4.59	4.59
2	Net Profit/(Loss) for the period from ordinary activities (Before Share of Profit/(Loss) of Associate, tax, Exceptional and/or Extraordinary items)	(72.00)	(208.22)	5.07	(99.97)	(266.46)	(266.46)
3	Net Profit/(Loss) for the period before tax (after Share of Profit/(Loss) of Associate, Exceptional and /or Extraordinary items)	(72.00)	(208.22)	5.07	(99.97)	(266.46)	(266.46)
4	Net Profit/ (Loss) for the period after tax (after Share of Profit/ (Loss)	(72.00)	(208.22)	5.07	580.1	2,580.1	2,580.1



Medicamen Biotech Ltd.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL1993PLC056594
E-mail: cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2023

(all figures are in Rs. Lacs, except EPS)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022
1	Total income from operations (net)	3749.48	2309.14	14034.62	11716.53	14332.96	11716.53
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
3	Net Profit/ (Loss) for the period before tax (after exceptional and / or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	404.60	275.47	1500.20	1490.64	1472.85	1489.71
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	404.60	275.47	1500.20	1490.64	1472.85	1489.71
6	Equity Share Capital	1265.11	1221.66	1265.11	1221.66	1265.11	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	3.25	2.25	12.04	12.20	11.82	12.19
	Diluted:	3.25	2.25	12.04	12.20	11.82	12.19

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2023. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share".
- The other expenses and Employee benefits expenses includes Rs. 3.50 Crores approximately incurred during Financial Year 2022-23 on creating domestic marketing network for Oncology products.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- The figures of the last quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figure upto the period end of the third quarter of the relevant financial year, which were subject to limited review.

For Medicamen Biotech Limited

Place: New Delhi
Date: 29.05.2023

Sd/-
Rahul Bishnoi
Chairman

मैगनम वेंचर्स लिमिटेड

सीआईएन: L21093DL1980PLC010492

जीकृत कार्यालय: एचएनओ-एमएन01, हब और ओक, ई-14, निचला भूतल, डिफेंस कॉलोनी, नई दिल्ली-110024
फोन: 011-42420015 | ईमेल: info@magnumventures.in | वेबसाइट: www.magnumventures.in

मार्च, 2023 को समाप्त तिमाही और वर्ष के लिए लेखा परीक्षित वित्तीय परिणामों के विवरण का अर्क

(राशि लाख रुपये में)

विवरण	तिमाही समाप्त			समाप्त वर्ष	
	31.03.2023 (लेखापरीक्षित)	31.12.2022 (अलेखापरीक्षित)	31.03.2022 (लेखापरीक्षित)	31.03.2023 (लेखापरीक्षित)	31.03.2022 (लेखापरीक्षित)
संचालन से कुल आय (शुद्ध)	12246.46	9611.14	11425.13	46549.88	33160.13
इस अवधि के लिए शुद्ध लाभ / (हानि) (कर से पहले, अपवादित और / या असाधारण आइटम)	1956.97	138.55	343.13	2667.25	788.13
कर से पहले की अवधि के लिए निवल लाभ / (हानि) (अपवादित और / या असाधारण वस्तुओं के बाद)	1956.97	138.55	342.74	6934.65	468.07
कर के बाद की अवधि के लिए शुद्ध लाभ / (हानि) (अपवादित और / या असाधारण वस्तुओं के बाद)	2069.54	179.42	289.42	7096.40	544.76

गुमशुदा की तलाश

सर्वसाधारण को सूचित किया जाता है कि एक लड़की (चित्र में दर्शाई गई), जिसका नाम: प्रीति, पुत्री: छोटे सैनी, निवासी: डी - 1, गली नं० 9 मंगा राम पार्क, उत्तम नगर दिल्ली, उम्र 16 वर्ष जोकि डी - 1, गली नं० 9 मंगा राम पार्क, उत्तम नगर दिल्ली, से गुम है। इस बाबत Fir No. 334/23 U/s 363 IPC, दिनांक 24.05.2023 से थाना बीदापुर, नई दिल्ली में दर्ज है। लड़की का शारीरिक ब्योरा इस प्रकार है: रंग: गोरा, कद: 5' फीट, चेहरा: गोल, शरीर: मध्यम, पहनावा: ब्लू टी-शर्ट और पिंक रंग का पजामा पहने हुए है। किसी व्यक्ति को इस गुमशुदा लड़की के बारे में कोई भी जानकारी/सूचना मिले तो इसकी सूचना निम्नलिखित को ई-मेल: cic@cbi.gov.in अथवा वेबसाइट: <http://cbi.nic.in> फोन नम्बर: 11-24368638 or 24368641 पर दें।



प्रीति

थानाध्यक्ष
बीदापुर, नई दिल्ली
फोन: 8750871025

DP/5681/DW/2023

आरसीसी सीमेन्ट्स लिमिटेड

सीआईएन : L26942DL1991PLC043776

पंजीकृत कार्यालय : 702, अरुणाचल बिल्डिंग, 19, बाराखम्मा रोड, कनाट प्लेस, नई दिल्ली-110001
दूरभाष : 011-43571044, फैक्स : 011-43571047, वेबसाइट : www.rccements.com,
ई-मेल आईडी : rccementslimited@gmail.com

31 मार्च, 2023 को समाप्त तिमाही तथा वित्तीय वर्ष हेतु स्टैंडअलोन अलेखापरीक्षित वित्तीय परिणामों का सारांश

(रु. लाख में)

क्रम सं.	विवरण	समाप्त तिमाही 31.03.2023 (लेखापरीक्षित)	समाप्त तिमाही 31.03.2022 (लेखापरीक्षित)	समाप्त वर्ष 31.03.2023 (लेखापरीक्षित)	समाप्त वर्ष 31.03.2022 (लेखापरीक्षित)
1.	प्रचालनों से कुल आय	0.54	1.89	6.33	3.52
2.	अवधि हेतु (कर, अपवादित तथा/अथवा असाधारण मदों से पूर्व) निवल लाभ/(हानि)	-3.48	-3.74	-11.40	-12.82
3.	कर पूर्व अवधि हेतु (अपवादित तथा/अथवा असाधारण मदों के पश्चात) निवल लाभ/(हानि)	-3.48	-3.74	-11.40	-12.82
4.	कर पश्चात अवधि हेतु (अपवादित तथा/अथवा असाधारण मदों के पश्चात) निवल लाभ/(हानि)	-3.48	-3.74	-11.40	-12.82
5.	अवधि हेतु कुल व्यापक आय (अवधि हेतु (कर पश्चात) लाभ/(हानि) तथा अन्य व्यापक आय (कर पश्चात) से निर्मित)	-3.48	-3.74	-11.40	-12.82
6.	इक्विटी शेयर पूंजी	560.2	560.2	560.2	560.2
7.	गत वर्ष के लेखापरीक्षित तुलन पत्र में प्रदर्शित के अनुसार आरक्षितियाँ (पुनर्मुल्यांकन आरक्षित को छोड़कर)			-221.86	-210.46
8.	आय प्रति शेयर (रु. 10/- प्रत्येक के) (सतत तथा असतत प्रचालनों हेतु): वैशिक: हाइल्यूड:	-0.06 -0.06	-0.07 -0.07	-0.20 -0.20	-0.23 -0.23

जोट :

उपर्युक्त सेबी (सूचीबद्धता दायित्व एवं प्रकटन अपेक्षाएं) विनियम, 2015 के विनियम 33 के तहत बीएसई के साथ दर्ज 31 मार्च, 2023 को समाप्त तिमाही तथा वित्त वर्ष के लेखापरीक्षित वित्तीय परिणामों के विस्तृत प्रारूप का सारांश है। उपर्युक्त वित्तीय परिणामों का पूर्ण प्रारूप बीएसई की वेबसाइट www.bseindia.com तथा कम्पनी की वेबसाइट www.rccements.com पर उपलब्ध है।

आरसीसीसी सीमेन्ट्स लिमिटेड के निदेशक मण्डल के लिए तथा उनकी ओर से

रु./-
सचिव नर्म
स्थान : नई दिल्ली
तिथि : 29.05.2023
प्रबन्ध निदेशक
डीआईएन : 0332035

फार्म सं. यूआरसी.2

अध्याय XXI के भाग I के तहत पंजीकरण के बारे में सूचना देने वाला विज्ञापन
[कंपनी अधिनियम, 2013 की धारा 374(बी) और कंपनी अधिनियम, 2013 के नियम 4(1) के अनुसार
कंपनियों (पंजीकरण के लिए अधिकृत) नियम, 2014]

1. नोटिस दिया जाता है कि कंपनी अधिनियम, 2013 की धारा 366 की उप-धारा (2) के अनुसार में, कंपनियों के रजिस्ट्रार, दिल्ली और हरियाणा को एक आवेदन किया गया है कि रिज्यू एंटरटेनमेंट एलएलपी, शेयरों द्वारा सीमित कंपनी के रूप में कंपनी अधिनियम 2013 के अध्याय XXI के भाग I के तहत पंजीकृत होना चाहता है।

2. कंपनी के प्रमुख उद्देश्य इस प्रकार हैं:

- फिल्मों और चलचित्रों के उत्पादन, वितरण या प्रदर्शनी और थिएटर, सिनेमा, स्टूडियो, और सिनेमेटोग्राफिक शो और प्रदर्शनियों के संचालन के व्यवसाय को जारी रखना

- सिनेमेटोग्राफ व्यापार और उद्योग के व्यवसाय को उनकी सभी शाखाओं और गतिविधियों में और विशेष रूप से सभी प्रकार की सिने फिल्मों, टॉकी फिल्मों, वीडियो फिल्मों, टेलीफिल्मों के निर्माण, उत्पादन, वितरण, उपयोग, प्रदर्शनी, आयात और निर्यात के व्यवसाय को चलाने के लिए, जिसमें प्रमुख रूप से फिल्मों में प्रदर्शन, वितरण, सिनेमेटोग्राफिक शो और प्रदर्शनियों के संचालन के व्यवसाय को शामिल किया गया है।